Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSK21542 for Prevention of CINV
NCT06593782Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Sep 2024
- Primary completion
- Jun 2025
- Modality
- Peptides, Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of hsk21542 in chemotherapy-induced nausea and vomiting (CINV) (3 arms), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoint: Acute Complete Response. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
hsk21542
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT06593782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06593782.